Guidelines and recent publications

It is a great pleasure to present to you our most recently developed Cervical, Vulval and Uterine cancer guidelines. These will be submitted for publication in the European Journal of Obstetrics and Gynecology and Reproductive Biology, similarly to the Ovarian and Endometrial Cancer guidelines.

We wish to sincerely thank the excellent multidisciplinary team of national and international experts who helped us develop and review these guidelines and of course our members all for the very constructive comments and critical review.

British Gynaecological Cancer Society and British Menopause Society guidelines
Management of menopausal symptoms following treatment of gynaecological cancer

August 2024

British Gynaecological Cancer Society (BGCS) ovarian, tubal and primary peritoneal cancer guidelines:  Recommendations for practice update 2024
July 2024

BMS/BGCS/BSGE joint guidance on management of women with unscheduled bleeding on HRT
May 2024

British Gynaecological Cancer Society/British Association of Gynaecological Pathology consensus for genetic testing in epithelial ovarian cancer in the United Kingdom
March 2024

Appendices:

Example PIL
Example Consent form
Example Genomics lead roles
Focused group questions and summary
A proposed whole genome sequencing pathway

Vulval Cancer guidelines:  An update on recommendations for practice 2023
December 2023
Click to view

BGCS Workforce Survey 2022

View Summary

View Presentation

BAGP guidance on POLE NGS testing in endometrial carcinoma
April 2022

The BAGP and BGCS guidelines and algorithmic flowchart for sending samples for testing for POLE testing.

Governance models to support patient safety when undergoing maximal effort cytoreductive surgery for advanced ovarian/fallopian tube/primary peritoneal cancer – A joint statement of ACPGBI, ASGBI, AUGIS and BGCS
10th December 2021

BAGP/BGCS 2021 FIGO Staging System for Vulvar Cancer: Summary and comparison with 2009 FIGO
Staging System 
November 2021

BGCS Uterine Cancer Guidelines: Recommendations for Practice
5th  November 2021

These guidelines have been published in the EJOG

The Royal College of Pathologists
March 2021

Standards and datasets for reporting cancers, dataset for histopathological reporting of cervical neoplasia.

Cervical Cancer guidelines
4 May 2020

These guidelines have been published in the EJOG

BGCS recommendations and guidance on patient- initiated follow- up (PIFU)
19 April 2020

These guidelines have been published in IJGC.

Sentinel Consensus Document for Vulval, Endometrial and Cervical cancer BGCS
17 January 2020

The BGCS is pleased to present these consensus statements on the use of sentinel lymph node staging in the management of cervical, endometrial and vulval malignancies. The statement reflects an analysis of the published evidence assessing this methodology combined with review of expert opinion and experience, and involved a formal “Delphi” process to achieve specialist consensus. The statement will inform forthcoming BGCS clinical guidelines for the management of these diseases, and we hope that they will also inform future NHS England Specialist Commissioning specifications and commissioning guidelines from the NHS in Scotland, Wales and Northern Ireland.

We would like to thank the specialist working group for the time and effort which went into developing these consensus statements, and particularly Christina Fotopoulou, Chair of the BGCS Guidelines Subgroup for leading the process.

NCRAS cervical cancer radical hysterectomy analysis
May 2019

Please see the executive summary paper from NCRAS summarising the findings of the analysis of MAS v open radical hysterectomy in England for cervical cancer 2013-16. The BGCS guidance statements for professionals and the public are also posted on this site. A formal peer review publication by NCRAS and BGCS officers will follow in due course.

View NCRAS summary paper
View BGCS professionals statement
View BGCS lay statement

Consensus document on risk stratified follow-up pathways in the management of ovarian, cervical, endometrial and vulval malignancies
1 August 2019

The BGCS is pleased to present a consensus document on risk-stratified follow-up pathways in the management of ovarian, cervical, endometrial and vulval malignancies. The statement reflects an analysis of the published evidence assessing the evidence for modernised, alternative follow-up strategies, combined with review of expert opinion and experience, in order to achieve specialist consensus. The statement will inform forthcoming BGCS clinical guidelines for the management of these diseases, and we hope that they will also inform future NHS England Specialist Commissioning specifications and commissioning guidelines from the NHS in Scotland, Wales and Northern Ireland.

We would like to thank the specialist working group for the time and effort which went into developing this document, and particularly Christina Fotopoulou, Chair of the BGCS Guidelines Subgroup for leading the process.

Sudha Sundar, BGCS President
Andy Nordin, BGCS Past President

British Gynaecological Cancer Society/British Association of Gynaecological Pathology consensus for germline and tumour testing for BRCA1/2 variants in ovarian cancer in the United Kingdom
19 January 2021

Appendix 1 – Pathology

Appendix 2 – Mutation result somatic and germline patient information sheet – BRCA

Appendix 3 – Mutation result somatic only patient information sheet – BRCA

Appendix 4 – Patient information sheet for tumour and germline testing – St George’s

IJGC document

NICE diagnostics guidance DG42: Testing strategies for Lynch syndrome in people with endometrial cancer
28 October 2020

On 28th October 2020, the National Institute of Health and Care Excellence (NICE) published a diagnostics guidance document¹ DG42: Testing strategies for Lynch syndrome in people with endometrial cancer. This document states that testing for Lynch syndrome should be offered when a person is diagnosed with endometrial cancer. Testing strategies include testing of the tumour tissue for Microsatellite Instability (MSI) or by immunohistochemistry (IHC) for Mismatch Repair proteins (MMR) followed by MLH1 promoter hypermethylation, if needed. This puts cellular pathology departments in the primary position of response when a diagnosis of endometrial cancer is made. Robust arrangements for communication with treating clinicians, genomic laboratory hubs and clinical geneticists are required.

The British Association of Gynaecological Pathologists, in association with the British Gynaecological Cancer Society and the Royal College of Pathologists, has produced a document with a flow chart of the proposed pathway. This is followed by a synopsis of the terminology for reports based on The British Association of Gynaecological Pathologists’ guidelines² on ‘Interpretation and Reporting Terminology for Mismatch Repair Protein Immunohistochemistry in Endometrial Cancer’ that has been endorsed by NICE in DG42.

1 Link to NICE DG42 https://www.nice.org.uk/guidance/dg42

2 Link to BAGP guidelines on reporting terminology for MMR IHC https://www.thebagp.org/resources/?wpdmc=bagp – guidance-documents

Raji Ganesan
President, British Association of Gynaecological Pathologists 

Sudha Sundar
President, British Gynaecological Cancer Society